{"classes":[{"categories":[{"measurements":[{"groupId":"OG000","value":"1"}]}]}],"denoms":[{"counts":[{"groupId":"OG000","value":"12"}],"units":"Participants"}],"description":"Number of patients in safety cohort with dose limiting toxicity (DLT)(including treatment delay)","groups":[{"description":"Feasibility measured by DLT rates in safety phase, Toxicities define DLTs and are summarized and reviewed to assess feasibility of administering the combination therapy with dasatinib","id":"OG000","title":"Treatment Induction (Enzyme Inhibitor Therapy & Chemotherapy)"}],"paramType":"NUMBER","populationDescription":"Patients with Philadelphia chromosome positive (Ph+) acute lymphoblastic leukemia (ALL)","reportingStatus":"POSTED","timeFrame":"Weeks 3 through 23 of treatment (From week 3 Induction through Intensification Block 1)","title":"Feasibility and Toxicity of an Intensified Chemotherapeutic Regimen Incorporating Dasatinib for Treatment of Children and Adolescents With Ph+ ALL Assessed by Examining Adverse Events","type":"PRIMARY","unitOfMeasure":"Pts with DLTs"}